Efficacy of Platinum-based Chemotherapy for Platinum-sensitive Recurrent Ovarian Cancer During PARP Inhibitor Treatment: A Multicenter Retrospective Study
Subsequent platinum-based chemotherapy in patients with platinum-sensitive recurrence during PARP inhibitor treatment demonstrated a low response rate and short PFS.
Authors
- Nanako Jonai
- Tsukasa Baba (ORCID: https://orcid.org/0000-0003-0066-3747)
- Eriko Takatori
- Fumiaki Takahashi (ORCID: https://orcid.org/0000-0001-9201-1089)
- Ami Jo
- TAKESHI AIDA
- YOHEI CHIBA
- Masahiro Kagabu (ORCID: https://orcid.org/0000-0003-0926-1015)
- Shunsuke Tatsuki
- Tadahiro Shoji (ORCID: https://orcid.org/0000-0002-9022-3333)
- Sho Sato (ORCID: https://orcid.org/0000-0002-5973-9091)
- Takayuki Nagasawa (ORCID: https://orcid.org/0000-0001-8279-4649)
- Yoshitaka Kaido
- Manabu Musashi
Institutions
- Iwate Medical University (JP)
- Japanese Red Cross Hadano Hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-11-29
- DOI
- https://doi.org/10.21873/anticanres.17910
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05